#nyse:pfe

[managermint]

InvestorPlace: Dow Jones Today: Plenty of Good News

InvestorPlace: Dow Jones Today: Plenty of Good News

With the help of broad-based leadership, the major U.S. equity benchmarks rallied Wednesday amid a flurry of decent headlines. Today’s leadership came by way of the technology and healthcare sectors, the two largest sector weights in the S&P 500, with some contributions from the defensive, high-yielding utilities group.

Source: Shutterstock

President Donald Trump took to Twitter (NYSE:TWTR),…

View On WordPress

[managermint]

InvestorPlace: Buy Pfizer Stock Before this Week’s Earnings Report Gives It a Bump Up With Pfizer Inc. (NYSE:PFE) stock slightly down year-to-date and gearing up to report their second-quarter earnings results on Tuesday investors are keeping their fingers crossed and hoping for a nice surprise amid a challenging market environment for American drugmakers.

[managermint]

InvestorPlace: Why Investors Should Buy the Dip in MRK Stock The collapse of healthcare stocks, especially drug companies, may have finally abated. Merck (NYSE:MRK) has fallen 12% from its April 3 high.

[marketexclusive]

Pfizer Inc. (NYSE:PFE) Challenges Businessmen To Come Up With Breast Cancer Solutions Pfizer Inc. (NYSE:PFE) is stepping up its battle against breast cancer. Perhaps in an effort to help Ibrance sales, a top breast cancer treatment, the biopharma giant says that patients suffering from this incurable cancer are more often than not overlooked in terms of care and treatment.

[marketexclusive]

FDA Agrees To Review IBRANCE (palbociclib) From Pfizer Inc. (NYSE:PFE)

FDA Agrees To Review IBRANCE (palbociclib) From Pfizer Inc. (NYSE:PFE)

The U.S. Food and Drug Administration (FDA) has agreed to review a supplemental New Drug Application (sNDA) of CDK 4/6 inhibitor, IBRANCE (palbociclib) from Pfizer Inc. (NYSE:PFE). The sNDA was granted Priority Review status with an accelerated timeline of six months instead of the initial 10 months. Under the guidance of the Prescription Drug User Fee Act (PDUFA) the FDA’s date for a decision…

View On WordPress

[marketexclusive]

CROSS TIMBERS ROYALTY TRUST (NYSE:CRT) Files An 8-K Results of Operations and Financial Condition

CROSS TIMBERS ROYALTY TRUST (NYSE:CRT) Files An 8-K Results of Operations and Financial Condition

CROSS TIMBERS ROYALTY TRUST (NYSE:CRT) Files An 8-K Results of Operations and Financial Condition Item2.02.Results of Operations and Financial Condition. On December19, 2016, the Registrant issued a news release announcing its monthly cash distribution to unitholders of record on December30, 2016. A copy of the news release is furnished as Exhibit 99.1. The information in this Current Report,…

View On WordPress

[marketexclusive]

Pfizer Inc. (NYSE:PFE) Buys 50% Stake In Ignite Immunotherapy

Pfizer Inc. (NYSE:PFE) Buys 50% Stake In Ignite Immunotherapy

In the wake of a comeback for cancer vaccines, Pfizer Inc. (NYSE:PFE) is holding onto an option of partnering with a startup in the field. The US pharma giant will be taking close to a 50% stake in the newly-formed cancer drug outfit Ignite Immunotherapy, based in Alameda, CA. Word has it that Pfizer could in the long run buy it out but only if its founders take the right direction insofar as…

View On WordPress

[marketexclusive]

Guggenheim has upgraded the stock of Pfizer Inc. (NYSE:PFE) Guggenheim has upgraded the stock of Pfizer Inc. (NYSE:PFE) to Neutral from its previous rating of.